Connect your AI

Savara SVRA Debt Issuance Cost Amortization

Debt Issuance Cost Amortization at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

$889K+5.3%

Innoviva, Inc.INVA

$364K-32.7%

ANI PharmaceuticalsANIP

$358K+10.5%

Amneal Pharmaceuticals, Inc.AMRX

$3.89M-42.9%

InsmedINSM

$1.38M-24.1%

TG TherapeuticsTGTX

$285K-6.3%

Other financials

Income statement

Revenue-—

Operating income-$39.0M-37.1%

Net income-$37.3M-40.0%

EPS (diluted)-$0.15-25.0%

Balance sheet

Cash & equivalents$38.8M+98.4%

Total debt$30.1M+1.8%

Total equity$176.0M+19.1%

Total assets$221.6M+17.1%

Cash flow

Operating cash flow-$33.0M-21.5%

CapEx$54.0K+1,700%

Free cash flow-$33.1M-21.7%

Valuation

Market cap$1.19B+134%

Enterprise value$1.19B+127%

P/S4,648.7×—

Profitability

Operating margin-19,183.3%—

Net margin-19,305.1%—

FCF margin-15,518.7%—

Returns & leverage

Return on equity-80%+4.7pp

Debt / equity0.2×0.0×

Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's debt issuance cost amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Savara's debt issuance cost amortization?: Savara (SVRA) reported debt issuance cost amortization of $160K in Q1 2026.
How has Savara's debt issuance cost amortization changed year-over-year?: Savara's debt issuance cost amortization increased by 128.6% year-over-year, from $70K to $160K.
What is the long-term trend for Savara's debt issuance cost amortization?: Over 4 years (2021 to 2025), Savara's debt issuance cost amortization has grown at a -4.8% compound annual growth rate (CAGR), from $552K to $453K.
What does debt issuance cost amortization mean?: Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).